Major food brands invest millions in rebrands to adapt to rising obesity drug use
Global food giants are overhauling product lines with smaller portions and cleaner labels as GLP-1 drugs curb snacking and change American eating habits.
Insights:
Major food and beverage companies in the US 
US are significantly altering their product portfolios and increasing capital spending in 2026 to address the rapid adoption of appetite-suppressing GLP-1 weight-loss drugs. This industry-wide shift involves reformulating products, shortening ingredient lists, and introducing smaller pack sizes to align with changing consumer eating patterns. Analysts suggest that these strategic reallocations are necessary as the rising use of these medications begins to materially impact the snack and beverage sectors.
US are significantly altering their product portfolios and increasing capital spending in 2026 to address the rapid adoption of appetite-suppressing GLP-1 weight-loss drugs. This industry-wide shift involves reformulating products, shortening ingredient lists, and introducing smaller pack sizes to align with changing consumer eating patterns. Analysts suggest that these strategic reallocations are necessary as the rising use of these medications begins to materially impact the snack and beverage sectors.
